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TOPICAL USE OF CHLORQUINALDOL*
HARRY M. ROBINSON, JR., M.D. AND MARK B. HOLLANDER, M.D.
In 1944, Jadassohn and his co-workers (1) published a report relative to a new
preparation which they found to be effective in the treatment of the pyodermas.
This preparation was laboratory-tested at Basle and ZUrich and found to have
both in vitro and in vivo bacteriostatic activity against staphylococci. Jadassohn
and his co-workers did comparison studies with another oxyquinoline derivative,
iodochlor-oxyquinoline, in the treatment of pyodermas and found 5, 7-dichioro-
8-hydroxyquinaldine (chlorquinaldol) to be superior. They stated that the oint-
ment containing this material had anti-mycotic value, particularly in mixed
infections produced by fungi and bacteria. Metaxas (2), Felkel (3), Sigg (4),
Schubert (5), and others (6, 7, 8) have confirmed these results. Less than three
percent of the 210 patients studied by Pierce (9) developed "sensitization or
irritation reactions." Leifer and Steiner (10) reported their experiences with two
patients who had become sensitized to other oxyquinoline derivatives and were
subsequently proved to have positive reactions to another derivative, 5-chioro-
8-hydroxyquinaldine as well. This was considered indicative of group sensitivity
to the halogenated oxyquinolines.
This study was conducted to determine the value of chlorquinaldol in derma-
tologic therapy.
PROCEDURE
Patients studied
Chlorquinaldol was supplied in two vehicles:
1. Petrolatum-beeswax ointment base containing 3 % of the active ingredient;
the finished product was light yellow in color.
2. A vanishing cream base containing 3% of the active ingredient; this prep-
aration was white in color, but turned a pale yellow after application to the
skin.
Patients selected
756 white and Negro patients of all ages with various dermatoses were included
in this study. The patients were obtained from the out-patient department of the
University Hospital and from other affiliated hospitals. Members of the derma-
tology staff also used these preparations in the treatment of their private pa-
tients. Whenever possible, the diagnoses and treatment results were confirmed
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by other members of the staff. This report represents a compilation of all of these
results.
Method of treatment
Treatment was initiated in 391 patients with the oily base ointment and in
365 with the greaseless base cream. The oily base preparation of chlorquinaldol
was used initially in all instances in which the dermatoses were dry, and the
greaseless base preparation was used initially in cases in which the dermatoses
were moist. In some instances, such as the treatment of the pyodermas or other
dermatoses where the underlying condition was complicated by secondary pyo-
genic infection, it proved desirable to initiate therapy with the oily base oint-
ment and, after the pyoderma cleared, to continue treatment with the greaseless
base cream. In this latter group of patients, instructions were given to remove
the surface detritus by compressing with warm water prior to the application of
the ointment. In all other dermatoses, the preparation was applied two or three
times daily.
RESULTS
Pyogenic disorders (Table I)
Chlorquinaldol was effective in the treatment of impetigo contagiosa and
other pyodermas, including infectious eczematoid dermatitis, dermatitis exfolia-
tiva neonatorum and paronychia. Of a total of 304 patients initiating therapy
for pyogenic disorders, 266 patients returned. From this latter group, improve-
ment was noted in 190, partial improvement in 42, and 34 showed no improve-
ment.
TABLE I
Results of treatment with c.hlorquinaldol in pyogenic skin disorders
Total
No. of
Diagnosis Starting
Treat-
ment
Impetigo contagiosa 98
Seborrheic dermititis 51
Pyodermas (extensive). . . . 42
Epidermophytosis, second-
arily infected 35 2 33 20 0
Otitis externa 38 5 33 26 1
Atopic dermititis, infected 22 2 20 16 0
Infectious eczematoid der-
matitis 9 7 5 0 0 0
Paronychia 4 4 2 0 0 0
Dermatitis exfoliativa
neonatorum 3 0 3 3 0 0 0 0
Pustular bacterid 2 0 2 0 0 2 0 0
Totals 304 38 266 190 42 34 6 3
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4 3 1
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2
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In atopic dermatitis, seborrheic dermatitis, epidermophytosis and otitis
externa in which the underlying dermatosis was complicated by secondary pyo-
genic infection, the preparations were of value in eradicating the infection in
from five to twelve days.
Results obtained in the study of dermatitis exfoliativa neonatorum (Ritter's
Disease) confirmed those reported by earlier investigators (1). Prompt improve-
ment was noted and all lesions underwent involution in two weeks. Two patients
with pyogenic paronychia and 2 with monilial paronychia were also treated. The
patients with the pyogenic infection recovered completely, while those with
monilial infection did not respond.
Non-p yogenic disorders (Table II)
One result observed with both the ointment and the cream was relief of
pruritus. In individuals who had pruritus without any underlying dermatosis,
there was little or no relief from itching.
A topic dermatitis: 87 patients with atopic dermatitis began treatment in this
series, and 18 were lost from observation. Of the remaining 69, 35 were definitely
improved, 20 were partially improved and 14 were not benefited. The most
notable effect in this condition was relief from pruritus. Topical therapy with
chlorquinaldol was used as an adjunct to afford the patient relief while a search
was made for etiological factors.
Contact dermatitis: 84 patients with contact dermatitis began treatment with
the ointment or cream, but 13 were lost from observation. Of the 71 cases fol-
lowed, 31 were completely relieved of symptoms, 24 were partially improved
TABLE II
Results of treatment with chtorquin.aldol in non-pyo genie skin disorders
.Diagnosis
Total
No. of
Cases
Starting
Treat-
ment
Cases
Lost
Total
No. of
Cases
Followed
Improved
I
Partially
Improved
Not Tm-
proved
Local
Irritation
H -'P
I" )
Atopic dermatitis
Contact dermatitis (all
causes)
Lichen simplex chronicus
(neurodermatitis)
Psoriasis
Mummular eczema
Stasis dermatitis
Pityriasis aiha
Erythrodermia desquama-
tiva
Pruritus ani
Miliaria rubra
87
84
68
37
28
22
8
2
18
10
18
13
8
6
4
4
2
0
3
2
69
71
60
31
24
18
6
2
15
8
35
31
35
2
12
8
2
2
0
7
20
24
18
17
8
6
2
0
9
0
14
16
7
12
4
4
2
0
6
1
3
2
3
0
2
1
0
0
1
1
1
1
0
0
0
0
0
0
0
0
Totals i 364 60 304 134 104 66 13 2
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and 16 patients failed to improve. During the course of treatment, all other
medication was withheld and, whenever possible, irritating factors such as soap,
detergents and solvents were eliminated from contact with the patients.
Lichen simplex chronicus: Of 68 patients, 8 were lost from observation. 35 of
the remaining 60 were greatly improved, 18 were partially improved and 7 did
not improve. As in atopic dermatitis, the major benefit was relief from pruritus.
Nummula: eczema: Of the 28 patients treated with the ointment or cream, 4
were lost from observation. Among the 24 patients followed, involution of lesions
occurred in 12, 8 were partially improved and 4 were not improved.
Stasis dermatitis: 22 patients were treated with ointment or cream. Four were
lost from observation, 8 improved, 6 partially improved and 4 were not benefited.
Erythrodermia desquamativa (Leiner's disease): Two infants with this condition
were treated with the ointment. Prompt improvement was noted and all lesions
subsided in two weeks.
Pruritus ani: The results obtained in the treatment of this condition were not
impressive. Fifteen of the patients were followed, 9 showing partial improve-
ment, 6 no improvement, and 3 were lost from observation. When the medica-
tion was discontinued, the condition recurred.
Miliaria rubra: Of this group of 10 patients, 2 were lost from observation, 7 of
the remaining 8 were relieved by the application of the cream, and 1 was not
benefited.
Conditions not benefited (Table III)
The medication proved to be of no value in herpes zoster, neurotic excoriations,
lichen scierosus et atrophicus, tinea capitis, trichophytosis corporis, uncompli-
cated epidermophytosis, pityriasis rosea, acne vulgaris, vitiligo, verruca vulgaris,
TABLE III
Non-pyogenic skin disorders not benefitted by chlorquinaldol
Diagnosis Total No. of Cases Effect on Pruritus or Pain
Herpes zoster 6 0
Neurotic excoriations 2 0
Lichen scierosus et atrophicus 2 +
Tinea capitis 9 0
Trichophytosis corporis 10 0
Epidermophytosis, uncomplicated 12 0
Pityriasis rosea 10 0
Acne vulgaris 6 0
Vitiligo 2 0
Verruca vulgaris 4 0
Varicella 2 0
Dermatitis exfoliativa 6 0
Erythema multiforme, papular 2 0
IJrticaria 2 0
Dermatitis medicamentosa 2 0
Lichen planus 11 +
Total 88
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varicella, dermatitis exfoliativa, papular erythema multiforme, uriticaria,
dermatitis medicamentosa, lichen planus, and pustular bacterid.
Reactions
Reactions of specific hypersensitivity were found in five patieiits as demon-
strated by positive patch tests. Nineteen patients developed evidence of primary
irritation due to local application of the ointment or cream. The patch tests in
this latter group gave negative results.
SUMMARY AND CONCLUSIONS
1. Seven hundred fifty six patients with various dermatoses were treated with
chlorquinaldol in an oily ointment base or greaseless base cream.
2. Chlorquinaldol proved to be of value in the topical treatment of pyodermas
and other dermatoses complicated by secondary pyogenic infection.
3. These preparations are effective antipruritic agents.
4. Chlorquinaldol is also of value as an adjunct in the treatment of atopic
dermatitis, seborrheic dermatitis, contact dermatitis, neurodermatitis, psoriasis,
nummular eczema, stasis dermatitis, otitis externa, erythrodermia desquama-
tiva, dermatitis exfoliative neonatorum, miliaria rubra and infectious eczematoid
dermatitis.
5. The preparation proved to be of no value in the treatment of herpes zoster,
neurotic excoriations, lichen sclerosus et atrophicus, tinea capitis, trichophytosis
corporis, uncomplicated epidermophytosis, pityriasis rosea, acne vulgaris, viti-
ligo, verruca vulgaris, varicella, dermatitis exfoliativa, papular erythema multi-
forme, urticaria, dermatitis medicamentosa, lichen planus and pustular bacterid.
6. Six hundred fifty eight patients returned for follow-up examinations. Of
these five developed a reaction of specific hypersensitivity and nineteen developed
local irritative phenomena.
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